← All trials
NCT05489237
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Apr 24, 2026
- Completion date
- Sep 13, 2026
- First posted
- Aug 5, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 143
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IDRx, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.